By Colin Kellaher

 

Merck & Co. on Friday said the European Commission approved expanded use of its blockbuster cancer drug Keytruda in combination with chemotherapy for the first-line treatment of certain patients with locally recurrent unresectable or metastatic triple-negative breast cancer.

The Kenilworth, N.J., drugmaker said the approval, its first for Keytruda in Europe in a breast-cancer setting, covers the treatment of adults whose tumors express PD-L1 with a combined positive score of at least 10 and who haven't received prior chemotherapy for metastatic disease.

Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is approved in numerous indications across a range of cancers around the world.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

October 22, 2021 07:21 ET (11:21 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Merck Charts.